Protective effects of metallothionein against dopamine quinone-induced dopaminergic neurotoxicity

FEBS Letters

Volumn 581, Issue 25, 2007, Pages 5003-5008

  Miyazaki, Ikuko ^a   Asanuma, Masato ^a   Hozumi, Hiroaki ^a   Miyoshi, Ko ^a   Sogawa, Norio ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Dopamine quinone; Metallothionein; Parkinson's disease; Zinc

Indexed keywords

DOPAMINE; LEVODOPA; METALLOTHIONEIN I; METALLOTHIONEIN II; ZINC;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; IN VITRO STUDY; METAL BINDING; MOUSE; NERVE ENDING; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WILD TYPE;

ANIMALS; CELL LINE; CYTOPROTECTION; DOPAMINE; DOPAMINE AGENTS; LEVODOPA; METALLOTHIONEIN; MICE; MICE, KNOCKOUT; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RNA, MESSENGER; ZINC;

MUS; PARKINSONIA;

EID: 34948859040     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2007.09.046     Document Type: Article

References (32)

1. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14 (1978) 633-643
2. Fornstedt B., Rosengren E., and Carlsson A. Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species. Neuropharmacology 25 (1986) 451-454
3. Kuhn D.M., Arthur Jr. R.E., Thomas D.M., and Elferink L.A. Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease. J. Neurochem. 73 (1999) 1309-1317
4. LaVoie M.J., Ostaszewski B.L., Weihofen A., Schlossmacher M.G., and Selkoe D.J. Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 11 (2005) 1214-1221
5. Whitehead R.E., Ferrer J.V., Javitch J.A., and Justice J.B. Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. J. Neurochem. 76 (2001) 1242-1251
6. Ahlskog J.E., and Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 16 (2001) 448-458
7. Asanuma M., Miyazaki I., and Ogawa N. Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox. Res. 5 (2003) 165-176
8. Kostrzewa R.M., Kostrzewa J.P., and Brus R. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease. Amino Acids 23 (2002) 57-63
9. Ogawa N., Edamatsu R., Mizukawa K., Asanuma M., Kohno M., and Mori A. Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa. Adv. Neurol. 60 (1993) 242-250
10. Hastings T.G., Lewis D.A., and Zigmond M.J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. USA 93 (1996) 1956-1961
11. Mytilineou C., Walker R.H., JnoBaptiste R., and Olanow C.W. Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J. Pharmacol. Exp. Ther. 304 (2003) 792-800
12. LaVoie M.J., and Hastings T.G. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J. Neurosci. 19 (1999) 1484-1491
13. Haque M.E., Asanuma M., Higashi Y., Miyazaki I., Tanaka K., and Ogawa N. Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells. Biochim. Biophys. Acta 1619 (2003) 39-52
14. Haque M.E., Asanuma M., Higashi Y., Miyazaki I., Tanaka K., and Ogawa N. Overexpression of Cu-Zn superoxide dismutase protects neuroblastoma cells against dopamine cytotoxicity accompanied by increase in their glutathione level. Neurosci. Res. 47 (2003) 31-37
15. Lai C.T., and Yu P.H. Dopamine- and L-β-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors. Biochem. Pharmacol. 53 (1997) 363-372
16. Offen D., Ziv I., Sternin H., Melamed E., and Hochman A. Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Exp. Neurol. 141 (1996) 32-39
17. Aschner M. Metallothionein (MT) isoforms in the central nervous system (CNS): regional and cell-specific distribution and potential functions as an antioxidant. Neurotoxicology 19 (1998) 653-660
18. Miyazaki I., Asanuma M., Higashi Y., Sogawa C.A., Tanaka K., and Ogawa N. Age-related changes in expression of metallothionein-III in rat brain. Neurosci. Res. 43 (2002) 323-333
19. Penkowa M. Metallothioneins are multipurpose neuroprotectants during brain pathology. FEBS Lett. 273 (2006) 1857-1870
20. Thornalley P.J., and Vasak M. Possible role for metallothionein in protection against radiation-induced oxidative stress. Kinetics and mechanism of its reaction with superoxide and hydroxyl radicals. Biochim. Biophys. Acta 827 (1985) 36-44
21. Hussain S., Slikker Jr. W., and Ali S.F. Role of metallothionein and other antioxidants in scavenging superoxide radicals and their possible role in neuroprotection. Neurochem. Int. 29 (1996) 145-152
22. Xie T., Tong L., McCann U.D., Yuan J., Becker K.G., Mechan A.O., Cheadle C., Donovan D.M., and Ricaurte G.A. Identification and characterization of metallothionein-1 and -2 gene expression in the context of (+/-)3,4-methylenedioxymethamphetamine-induced toxicity to brain dopaminergic neurons. J. Neurosci. 24 (2004) 7043-7050
23. Palmiter R.D. Regulation of metallothionein genes by heavy metals appears to be mediated by a zinc-sensitive inhibitor that interacts with a constitutively active transcription factor, MTF-1. Proc. Natl. Acad. Sci. USA 91 (1994) 1219-1223
24. Haq F., Mahoney M., and Koropatnick J. Signaling events for metallothionein induction. Mutat. Res. 533 (2003) 211-226
25. Miyazaki I., Asanuma M., Diaz-Corrales F.J., Miyoshi K., and Ogawa N. Dopamine agonist pergolide prevents levodopa-induced quinoprotein formation in parkinsonian striatum and shows quenching effects on dopamine-semiquinone generated in vitro. Clin. Neuropharmacol. 28 (2005) 155-160
26. Franklin K.B.J., and Paxinos G. The Mouse Brain in Stereotaxic Coordinates (1997), Academic Press, San Diego
27. Paz M.A., Fluckiger R., Boak A., Kagan H.M., and Gallop P.M. Specific detection of quinoproteins by redox-cycling staining. J. Biol. Chem. 266 (1991) 689-692
28. Ajjimaporn A., Swinscoe J., Shavali S., Govitrapong P., and Ebadi M. Metallothionein provides zinc-mediated protective effects against methamphetamine toxicity in SK-N-SH cells. Brain Res. Bull. 67 (2005) 466-475
29. Wong E.S., Tan J.M., Wang C., Zhang Z., Tay S.P., Zaiden N., Ko H.S., Dawson V.L., Dawson T.M., and Lim K.L. Relative sensitivity of parkin and other cysteine-containing enzymes to stress-induced solubility alterations. J. Biol. Chem. 282 (2007) 12310-12318
30. Miyazaki I., Asanuma M., Diaz-Corrales F.J., Fukuda M., Kitaichi K., Miyoshi K., and Ogawa N. Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone formation-related molecules. FASEB J. 20 (2006) 571-573
31. Asanuma M., Miyazaki I., Higashi Y., Tanaka K., Haque M.E., Fujita N., and Ogawa N. Aggravation of 6-hydroxydopamine-induced dopaminergic lesions in metallothionein-I and -II knock-out mouse brain. Neurosci. Lett. 327 (2002) 61-65
32. Rojas P., and Rios C. Metallothionein inducers protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in mice. Neurochem. Res. 22 (1997) 17-22